Abstract

*Hafiz Muhammad Asad Shakeel, Muhammad Umer Ali Ayub and Muhammad Sohail

ABSTRACT

Objective: This research's main objective was to evaluate HER2/New receptors' condition in patients of breast cancer. Place and Duration of study: This research was conducted in DHQ Hospital Faisalabad's surgical department in six months, from October 2019 to March 2020. Materials and Methods: This study included a total of 100 outdoor patients receiving surgery. This study included female patients diagnosed with breast cancer ages 20-65. Only patients with ductal/lobular carcinoma were included. This study excluded patients with recurrence of breast cancer, and those who refused histopathology were excluded. All patients or parents received informed consent. The approval of the Ethical Committee was taken. To collect patient data, a pre-designed proforma was used. Sampling was sent to reliable HER2/Neu laboratory, tumour staging, histopathology, progesterone and estrogen. Immunohistochemical studies were performed, and Hercep was used after tissue biopsy. Three positive plus points and less than three negative ones. For data analysis, SPSS version 16 has been used. Results: One Hundred patients in total were selected. The average patient number was 43.88 years. HER2/New receptors were respectively positive and negative at 40% and 60%. Twenty-one percent of patients who were diagnosed with Grade 1, 35 had Grade 2, and 44 percent had Grade 3 tumour. Ductal and lobular carcinoma were 87% and 13% respectively. In 75% of patients, the estrogen receptor(ER) is positive, while 25% have negative ER receptors. Thirty-five per cent of patients reported negative progesterone (PR) receptors, while 65 per cent reported positive PR receptors. Conclusion: This study shows a higher incidence of HER2/New expression receptors. The highest incidence was in patients with grade 3 tumours. In most cases, PR and ER were positive, and HER2/New receptors were not related to age or obesity.